Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

BACKGROUND: Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T manufacture abroad. Relma‐cel (JWCAR029), an anti‐CD19 product produc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Zhitao, Yang, Haiyan, Guo, Ye, Li, Wenyu, Zou, Dehui, Zhou, Daobin, Wang, Zhao, Zhang, Mingzhi, Wu, Jianqiu, Liu, Hui, Zhang, Pian, Yang, Su, Zhou, Zisong, Zheng, Hongxia, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897944/
https://www.ncbi.nlm.nih.gov/pubmed/33382529
http://dx.doi.org/10.1002/cam4.3686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897944/
https://www.ncbi.nlm.nih.gov/pubmed/33382529
http://dx.doi.org/10.1002/cam4.3686

Ejemplares similares